OncoRevive
Oncorevive provides a blood test that combines nanotechnology, cancer biology, and AI to analyze multiple biomarker categories simultaneously, delivering results in under two hours. The platform is approximately four times cheaper than existing liquid biopsy methods and requires 20 times less capital investment, enabling adoption in hospitals and pathology labs. This multiomic approach supports real-time cancer treatment monitoring for clinicians and researchers.
- Healthcare Technology
- Biotechnology
- Medical Devices
- Artificial Intelligence
- Data & Analytics
- Hardware
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Current liquid biopsy technologies are not multiomic and require up to two weeks to deliver results, preventing real-time cancer treatment monitoring. Most existing tests can only detect a single biomarker category, such as DNA, protein, or lipid, leaving gaps in the diagnostic picture. Additionally, high capital costs of current technologies block their adoption in many hospitals and pathology labs.
Solution
Oncorevive provides a blood test that combines nanotechnology, cancer biology, and AI to analyze multiple biomarker categories simultaneously, delivering a comprehensive diagnostic picture in under two hours. This multiomic approach enables doctors to monitor different cancer biomarkers during treatment and gain real-time insight into how a patient is responding. The platform is designed to be four times cheaper than existing testing methods, reducing costs for patients and lowering financial barriers for healthcare providers. By unifying fragmented diagnostic workflows into a single same-day test, Oncorevive aims to replace costly, multi-step testing with one comprehensive solution.
Target Audience
Primary customers are hospitals, pathology laboratories, and oncology clinics that need comprehensive, same-day cancer detection and treatment monitoring at a lower cost than existing fragmented testing options. The platform also serves medical oncologists, cancer researchers, and clinical research organizations seeking rapid multiomic data for clinical trials.
Features
- Multiomic analysis covering multiple biomarker categories in a single blood draw
- AI-driven data integration to deliver a comprehensive diagnostic picture in under two hours
- Nanotechnology-based detection platform enabling low-cost, scalable testing
- Same-day results designed for real-time treatment response monitoring
- Cost structure approximately 4X cheaper than current liquid biopsy technologies
- Requires approximately 20X less capital investment than existing technologies, enabling adoption in remote areas
- Non-invasive blood test suitable for early-stage cancer detection